1887

Abstract

Adult immunocompetent mice inoculated with Ebola (EBO) or Marburg (MBG) virus do not become ill. A suckling-mouse-passaged variant of EBO Zaire ’76 (‘mouse-adapted EBO-Z’) causes rapidly lethal infection in adult mice after intraperitoneal (i.p.) inoculation, but does not cause apparent disease when inoculated subcutaneously (s.c.). A series of experiments showed that both forms of resistance to infection are mediated by the Type I interferon response. Mice lacking the cell-surface IFN-α/β receptor died within a week after inoculation of EBO-Z ’76, EBO Sudan, MBG Musoke or MBG Ravn, or after s.c. challenge with mouse-adapted EBO-Z. EBO Reston and EBO Ivory Coast did not cause illness, but immunized the mice against subsequent challenge with mouse-adapted EBO-Z. Normal adult mice treated with antibodies against murine IFN-α/β could also be lethally infected with i.p.-inoculated EBO-Z ’76 or EBO Sudan and with s.c.-inoculated mouse-adapted EBO-Z. Severe combined immunodeficient (SCID) mice became ill 3–4 weeks after inoculation with EBO-Z ’76, EBO Sudan or MBG Ravn, but not the other viruses. Treatment with anti-IFN-α/β antibodies markedly accelerated the course of EBO-Z ’76 infection. Antibody treatment blocked the effect of a potent antiviral drug, 3-deazaneplanocin A, indicating that successful filovirus therapy may require the active participation of the Type I IFN response. Mice lacking an IFN-α/β response resemble primates in their susceptibility to rapidly progressive, overwhelming filovirus infection. The outcome of filovirus transfer between animal species appears to be determined by interactions between the virus and the innate immune response.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-82-6-1365
2001-06-01
2020-08-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/82/6/0821365a.html?itemId=/content/journal/jgv/10.1099/0022-1317-82-6-1365&mimeType=html&fmt=ahah

References

  1. Basler C. F., Want X., Muhlberger E., Volchkov V., Paragas J., Klenk H. D., Garcia-Sastre A., Palese P.. 2000; The Ebola virus VP35 protein functions as a type I IFN antagonist. Proceedings of the National Academy of Sciences, USA97:12289–12294
    [Google Scholar]
  2. Bowen E. T. W., Platt G. S., Lloyd G., Baskerville A., Harris W. J., Vella E. E.. 1977; Viral haemorrhagic fever in southern Sudan and northern Zaire. Lancet i571–573
    [Google Scholar]
  3. Bowen E. T. W., Platt G. S., Simpson D. I. H., McArdell L. B., Raymond R. T.. 1978a; Ebola haemorrhagic fever: experimental infection of monkeys. Transactions of the Royal Society of Tropical Medicine and Hygiene72:188–191
    [Google Scholar]
  4. Bowen E. T. W., Baskerville A., Cantell K., Mann G. F., Simpson D. I. H., Zuckerman A. J.. 1978b; The effect of interferon on experimental Ebola virus infection in rhesus monkeys. In Ebola Virus Hemorrhagic Fever pp245–252 Edited by Pattyn S. R.. Amsterdam: Elsevier/North Holland;
    [Google Scholar]
  5. Bray M., Huggins J. W.. 1998; Antiviral therapy of haemorrhagic fevers and arbovirus infections. Antiviral Therapy3:53–79
    [Google Scholar]
  6. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. W.. 1998; A mouse model for evaluation of Ebola prophylaxis and therapy. Journal of Infectious Diseases178:651–661
    [Google Scholar]
  7. Bray M., Driscoll J., Huggins J. W.. 2000; Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosylhomocysteine hydrolase inhibitor. Antiviral Research45:135–147
    [Google Scholar]
  8. Connolly B., Steele K., Davis K., Geisbert T., Kell W., Jaax N., Jahrling P.. 1999; Pathogenesis of experimental Ebola virus infection in guinea pigs. Journal of Infectious Diseases179:203–217
    [Google Scholar]
  9. Durbin J. E., Hackenmiller R., Simon M. C., Levy D. E.. 1996; Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell84:443–450
    [Google Scholar]
  10. Frese M., Kochs G., Feldmann H., Hertkorn C., Haller O.. 1996; Inhibition of bunyaviruses, phleboviruses and hantaviruses by human MxA protein. Journal of Virology70:915–923
    [Google Scholar]
  11. Gresser I., Tovey M. G., Bandu M. T., Maury C., Brouty-Boye D.. 1976; Role of interferon in the pathogenesis of virus diseases, as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease and influenza viruses. Journal of Experimental Medicine144:1316–1323
    [Google Scholar]
  12. Haller O., Frese M., Kochs G.. 1998; Mx proteins: mediators of innate resistance to RNA viruses. Revue Scientifique et Technique O.I.E17:220–230
    [Google Scholar]
  13. Harcourt B. H., Sanchez A., Offermann M. K.. 1998; Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology252:179–188
    [Google Scholar]
  14. Harcourt B. H., Sanchez A., Offermann M. K.. 1999; Ebola virus selectively inhibits responses to interferons, but not to interleukin-1β, in endothelial cells. Journal of Virology73:3491–3496
    [Google Scholar]
  15. Hefti H. P., Frese M., Landis H., Di Paolo C., Aguzzi A., Haller O., Pavlovic J.. 1999; Human MxA protein protects mice lacking a functional alpha/beta interferon system against La Crosse virus and other lethal viral infections. Journal of Virology73:6984–6991
    [Google Scholar]
  16. Hofmann R., Kunz C.. 1970; A strain of ‘Marburg virus’ pathogenic to mice. Archiv für die gesamte Virusforschung174:932–945
    [Google Scholar]
  17. Huggins J. W., Zhang Z., Monath T. I.. 1995; Inhibition of Ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors. Antiviral Research Suppl. 1122
  18. Jaax N., Geisbert T. W., Vogel A., Topper M., Jahrling P.. 1996; Lethal experimental infection of rhesus monkeys with Ebola Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Archives of Pathology and Laboratory Medicine120:140–155
    [Google Scholar]
  19. Jahrling P., Geisbert T., Geisbert J., Swearengen J., Bray M., Jaax N., Huggins J., LeDuc J., Peters C. J.. 1999; Evaluation of immune globulin and recombinant interferon α-2b for treatment of experimental Ebola virus infections. Journal of Infectious Diseases179:224–234
    [Google Scholar]
  20. Katze M.. 1992; The war against the interferon-induced dsRNA-activated protein kinase: can viruses win?. Journal of Interferon Research12:241–248
    [Google Scholar]
  21. Meager A.. 1998; Interferons alpha, beta and omega In Cytokines . pp98–124 Edited by Mire-Sluis A. R., Thorpe R.. New York: Academic Press;
  22. Muller U., Steinhoff U., Reis L.. 1994; Functional role of type I and type II interferons in antiviral defense. Science264:1918–1924
    [Google Scholar]
  23. Pattyn S., Jacob W., van der Groen G., Piot P., Courteille G.. 1977; Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet i573–574
    [Google Scholar]
  24. Peters C. J., Rollin P., Ksiazek T. G., Murphy F. A.. 1996; Filoviridae : Marburg and Ebola viruses In Fields Virology . pp1161–1176 Edited by Fields B. N., Knipe D. M., Howley P. M. Philadelphia: Lippincott–Raven;
  25. Pfiefer K., Ushijima H., Lorenz B., Muller W. E., Schroder H. C.. 1993; Evidence for age-dependent impairment of antiviral 2′,5′-oligoadenylate synthetase/ribonuclease L-system in tissues of rat. Mechanisms of Ageing and Development67:101–114
    [Google Scholar]
  26. Ryabchikova E., Kolesnikova L., Netesov S.. 1998; Animal pathology of filovirus infections. Current Topics in Microbiology and Immunology235:147–173
    [Google Scholar]
  27. Sanchez A., Ksiazek T. G., Rollin P. E., Peters C. J., Nichol S. T., Khan A. S., Mahy B. W.. 1995; Reemergence of Ebola virus in Africa [editorial]. Emerging Infectious Diseases1:96–97
    [Google Scholar]
  28. Siegert R.. 1973; Marburg virus. Monographs in Virology11:98–153
    [Google Scholar]
  29. Sullivan N. J., Sanchez A., Rollin P. E., Yang Z.-Y., Nabel G. J.. 2000; Development of a preventive vaccine for Ebola virus infection in primates. Nature408:605–609
    [Google Scholar]
  30. Thimme R., Frese M., Kochs G., Haller O.. 1995; Mx1 but not MxA confers resistance against tick-borne Dhori virus in mice. Virology211:296–301
    [Google Scholar]
  31. Trgovcich J., Aronson J. F., Eldridge J. C., Johnston E. E.. 1999; TNF-alpha, interferon and stress response induction as a function of age-related susceptibility to fatal Sindbis virus infection of mice. Virology263:339–348
    [Google Scholar]
  32. van den Broek M. F., Muller U., Huang S., Aguet M., Zinkernagel R. M.. 1995a; Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. Journal of Virology69:4792–4796
    [Google Scholar]
  33. van den Broek M. F., Muller U., Huang S., Zinkernagel R. M., Aguet M.. 1995b; Immune defense in mice lacking type I and/or type II interferon receptors. Immunological Reviews148:5–18
    [Google Scholar]
  34. van der Groen G., Jacob W., Pattyn S. R.. 1979; Ebola virus virulence for newborn mice. Journal of Medical Virology4:239–240
    [Google Scholar]
  35. Vanderzanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., Jahrling P., Huggins J., Schmaljohn A., Schmaljohn C.. 1998; DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology246:134–144
    [Google Scholar]
  36. Wilson J., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A., Hart M. K.. 2000; Epitopes involved in antibody-mediated protection from Ebola virus. Science287:1664–1666
    [Google Scholar]
  37. Zaki S. R., Goldsmith C. S.. 1998; Pathologic features of filovirus infections in humans. Current Topics in Microbiology and Immunology235:97–116
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-82-6-1365
Loading
/content/journal/jgv/10.1099/0022-1317-82-6-1365
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error